GlassScriptPhysician profile
Cynthia Lockerd
NPI 1750378758
$2,852.34
in general payments reported to CMS, 2019-2025
24 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.77 · 2022: $793 · 2023: $593 · 2024: $715 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $687.97 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $477.88 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $374.45 | 2022-2025 | |
| Pfizer INC. | $249.89 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $177.46 | 2021-2025 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $126.34 | 2022-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Lilly USA, LLC | $114.70 | 2022-2025 | Mounjaro, Zepbound, Basaglar |
| Axsome Therapeutics, INC. | $92.37 | 2024-2025 | Auvelity |
| Alkermes, INC. | $87.87 | 2024-2025 | Vivitrol |
| Glaxosmithkline, LLC. | $63.11 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.26 | 2021-2023 | Jardiance |
| Nestle Healthcare Nutrition INC. | $43.96 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.74 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.33 | 2022-2023 | |
| Exact Sciences Corporation | $34.81 | 2023-2024 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $34.25 | 2025 | Uzedy |
| Idorsia Pharmaceuticals US INC | $24.36 | 2022 | |
| Sanofi Pasteur INC. | $20.70 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.69 | 2022 | |
| Neurelis, INC. | $20.60 | 2023 | Valtoco |
| Abbott Laboratories | $19.42 | 2025 | Freestyle Libre 3 |
| Abiomed | $17.26 | 2023 | Impella |
| Amgen INC. | $16.86 | 2025 | Otezla, Repatha |
| Sunovion Pharmaceuticals INC. | $16.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Lockerd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.